Article

Custom treatment improves overcorrection, night vision

Author(s):

An off-label use of the CustomCornea procedure (Alcon Laboratories) to re-treat symptomatic eyes of patients who had undergone a previous refractive procedure produces dramatic reductions in visual symptoms, according to James J. Salz, MD.

"An important point to be emphasized with these patients is that information from a large area of the cornea needs to be captured with the pupil dilated. For example, capturing a 7-mm area provides very reliable data for a 6.5-mm pupil compared with capturing a 6-mm area," Dr. Salz stated.

At the recent annual meeting of the American Society of Cataract and Refractive Surgery, he reported the results of CustomCornea treatment in five patients who were re-treated after a refractive procedure. Dr. Salz pointed out that in a patient with a 7.5-mm pupil compared with a 6-mm pupil, 75% of the spherical aberration, 46% of the coma, and 44% of other aberrations would be missed with the smaller pupil size.

The five cases In one case the patient underwent LASIK after radial keratotomy (RK) and had high higher-order aberrations. After the RK, the patient was overcorrected and the LASIK achieved a good visual outcome. However, the quality of the night vision was poor. One preoperative map showed extensive high-order aberrations; and a second map showed dramatic improvement. In this case, Dr. Salz cautioned that checking the pupil size is extremely important, because in the first map the pupil size was 9 mm and in the second it was 5 mm. With both maps and the same pupil size of 6.5 mm, there was still a significant improvement.

"It is unfair to make this type of comparison with different pupil sizes, because simply reducing the pupil size can cause the map to look dramatically better," he said.

The second patient had undergone LASIK for myopia with a small ablation diameter (possibly less than 6 mm) and had a great deal of glare, ghosting, and double vision during night driving. His refractive error was about -0.75 D in each eye. Preoperatively, spherical aberration seemed to be the primary problem (aberration about 0.7 in each eye). In the first eye that underwent customized treat-ment, the spherical aberration decreased to 0.3 and the coma decreased slightly 3 months postoperatively. The patient had a dramatic improvement in night vision symptoms. The second eye then was treated and the results were the same.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.